Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: “The approval of TAGRISSO for patients with Stage III, unresectable EGFR-mutated non-small cell lung cancer ...
FDA has approved Tagrisso for the treatment of adult patients with locally advanced, unresectable NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based ...